The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 68 (elevated attention) · dilution pressure high · listing risk low · governance risk low · runway 7.3 mo · strongest signal: Registered direct (Aug 11, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway 6–12 months) coexists with live selling machinery (registered direct, shelf effective, shelf filed, offering (424b)). Base case is a discounted raise; the question is when, not if.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 11, 2026 | ▼ Registered direct | “rdo” language in 8-K (EX-99.1) filed 2026-08-11 filing | 36 |
| Aug 11, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-08-11 (accepted 17:29 ET) filing | 23 |
| Aug 7, 2026 | ▼ Offering (424B) | 424B3 prospectus supplement 2026-08-07; 3 prior 424B filings in 12m filing | 27 |
| Aug 7, 2026 | ▼ Shelf effective | EFFECT notice 2026-08-07 filing | 21 |
| Jul 30, 2026 | ▼ Shelf filed | S-3 filed 2026-07-30 filing | 35 |
| Jun 30, 2026 | ▼ Runway 6–12 months | ~7.3 months runway: liquidity $886,471 as of 2026-06-30, burn $1,454,448/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 26 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $886,471 vs current liabilities $12,106,185 filing | 21 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →